RTP Mobile Logo
Prostate Cancer Update, Issue 1, 2010
Released July 2010

Featuring interviews with Drs A Oliver Sartor, Nancy A Dawson, Anthony Zietman and E David Crawford. (Audio and Text Format)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    An estimated 220,000 new cases of prostate cancer are diagnosed yearly in the United States and account for approximately one third of new cancer cases among men. Published results from clinical trials lead to the emergence of new local and systemic therapeutic approaches, along with changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing urologist, radiation oncologist and medical oncologist must be well informed of these advances. By providing information on the latest research developments and expert perspectives, this CME activity assists clinicians with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Appraise the clinical benefits of adjuvant radiation therapy for patients with locally advanced or high-risk prostate cancer.
    • Apply the results of existing and emerging research on the choice and timing of endocrine therapy alone or with radiation therapy to the care of patients with localized, biochemically recurrent or metastatic prostate cancer.
    • Communicate the benefits and risks of taxane-based chemotherapy regimens to patients with recurrent prostate cancer.
    • Summarize emerging efficacy and safety data with targeted agents in castration-resistant prostate cancer, including anti-angiogenic therapy, microtubule stabilizers, specific endothelin A receptor antagonists, immunomodulatory agents and novel inhibitors of testosterone synthesis or activity.
    • Counsel appropriately selected patients about the availability of ongoing clinical trials.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY
    Dr Zietman had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SartorAdvisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Sanofi-Aventis; Consulting Agreements: Celgene Corporation, GlaxoSmithKline, GPC Biotech, Pfizer Inc, Sanofi-Aventis; Paid Research: AstraZeneca Pharmaceuticals LP, GPC Biotech. Dr DawsonSpeakers Bureau: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis. Dr CrawfordEmployee: Ferring; Meeting Participant/Lecturer: Endocare, Endo Pharmaceuticals, Ferring, GlaxoSmithKline, Oncura, Sanofi-Aventis, Watson Pharmaceuticals Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Sanofi-Aventis.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2010
    Expiration date: July 2011

Acknowledge and close

Prostate Cancer Update, Issue 1, 2010
Released July 2010

Featuring interviews with Drs A Oliver Sartor, Nancy A Dawson, Anthony Zietman and E David Crawford. (Audio and Text Format)